Roth Capital analyst Michael Higgins was out pounding the table on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) Tuesday, resuming coverage with a Buy rating and a …
Today’s healthcare sector offered a great deal of rumble and tumble with the following volatile stocks making headlines today: AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), …
Palatin Technologies, Inc. (NYSEMKT:PTN) announced today that it intends to offer and sell, subject to market and other conditions, 25,384,616 shares of its …
Yesterday, Palatin Technologies, Inc. (NYSEMKT:PTN) announced its fiscal first quarter results for 2017, with Roth Capital analyst Joseph Pantginis determining that “all eyes” …
Canaccord analyst John Newman speculates on Palatin Technologies, Inc. (NYSEMKT:PTN) ahead of clinical data and partnership updates with a bullish forecast, reiterating a …
Palatin Technologies, Inc. (NYSEMKT:PTN) shares were on a close to 18% rise after market close yesterday after the firm’s pipeline drug bremelanotide (BMT), …
Palatin Technologies, Inc. (NYSEMKT:PTN) shares jumped 18% today after the company’s key pipeline drug bremelanotide, designed to treat female sexual dysfunction (FSD), hit …
Healthcare stocks Palatin Technologies (NYSEMKT:PTN), Novocure Ltd (NASDAQ:NVCR), and AveXis Inc (NASDAQ:AVXS) are reaping the benefits of clinical and corporate progress updates that have sent the …
In a research report released Tuesday, Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) with a $6.
Analysts are weighing in on the biotechnology giant Gilead Sciences, Inc. (NASDAQ:GILD) and pharmaceutical company Palatin Technologies, Inc.